Abstract:Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as TGF-β and PDGFs), cytokines (including TNF-α, IL-1, IL-6, IL-10 and IL-4), and neurohumoral pathways trigger fibrogenic signaling cascades through binding to surface receptors, and activation of downstream signaling cascades. In addition, matricellular macromolecules are deposited in the remodeling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review manuscript discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction (HFrEF and HFpEF), genetic cardiomyopathies and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodeling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.

Cardiac Fibrosis: Cellular Effectors, Molecular Pathways, and Exosomal Roles

Diagnostic and Therapeutic Properties of Exosomes in Cardiac Fibrosis

Emerging Roles of Fibroblasts in Cardiovascular Calcification

Current concepts in the epigenetic regulation of cardiac fibrosis

Extracellular matrix remodeling and cardiac fibrosis

Cardiac Fibrosis: New Insights into the Pathogenesis

Targeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis

Epigenetic Regulation of Fibroblasts and Crosstalk between Cardiomyocytes and Non-Myocyte Cells in Cardiac Fibrosis

m6A epitranscriptomic and epigenetic crosstalk in cardiac fibrosis

EphrinB2 Regulates Cardiac Fibrosis Through Modulating the Interaction of Stat3 and TGF-β/Smad3 Signaling

Proteomic Insights into Cardiac Fibrosis: from Pathophysiological Mechanisms to Therapeutic Opportunities

The Function and Therapeutic Potential of lncRNAs in Cardiac Fibrosis

Myocardial fibrosis from the perspective of the extracellular matrix: mechanisms to clinical impact

Exosomes Derived from Cardiomyocytes Promote Cardiac Fibrosis Via Myocyte-Fibroblast Cross-Talk.

Exosomes As Mediators and Biomarkers in Fibrosis

Cardiac fibrosis.

Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification

Endothelial Mesenchymal Transition in Cardiac Fibrosis

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress

Fibroblast Diversity and Epigenetic Regulation in Cardiac Fibrosis